[Skip to Navigation]
Comment & Response
April 29, 2021

Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab—Diving Deeper for Safety and Efficacy

Author Affiliations
  • 1Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India
JAMA Ophthalmol. 2021;139(6):677-679. doi:10.1001/jamaophthalmol.2021.1037

To the Editor We read with great excitement the article by Woo et al.1 We congratulate the authors on the detailed analysis and for publishing the results of a new avenue in the treatment of neovascular age-related macular degeneration. Our group has been trying to understand various aspects of biosimilars in retinal diseases for the past 2 years.2,3 We have published on the regulatory aspects related to biosimilars in ophthalmology.4 We are curious to understand a few points in relation to the article by Woo et al.1

Add or change institution